Keyphrases
Predictive Biomarker
100%
Advanced Prostate Cancer
100%
Pembrolizumab
100%
Microsatellite Instability-high (MSI-H)
100%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
60%
Patient Selection
40%
TMB-H
40%
Programmed Death-ligand 1 (PD-L1)
20%
Clinical Data
20%
Small Populations
20%
Biomarker Testing
20%
Checkpoint Inhibitors
20%
Single-center Study
20%
Blood Tumor mutational Burden
20%
Medicine and Dentistry
Biological Marker
100%
Prostate Cancer
100%
Pembrolizumab
100%
Programmed Death-Ligand 1
20%
Immunotherapy
20%
Microsatellite Instability
20%
Tumor Mutation Burden
20%
Pharmacology, Toxicology and Pharmaceutical Science
Biological Marker
100%
Prostate Cancer
100%
Pembrolizumab
100%
Immunotherapy
20%
Neoplasm
20%
Neuroscience
Lambrolizumab
100%
Prostate
60%
Immunotherapy
20%
Microsatellite Instability
20%
Biochemistry, Genetics and Molecular Biology
Pembrolizumab
100%
PD-L1
20%
Microsatellite Instability
20%